Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Summary

The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Timeline

Start

2022-12-14

Primary completion

2028-03-31

Completion

2028-03-31

Publications

• Procyk G, Tyrna P, Mlynarczuk-Bialy I, Budzianowski J, Olasinska-Wisniewska A, Kochman J, Gasecka A. Lipoprotein(a) and clinical outcomes after transcatheter aortic valve implantation: a prospective, multicenter cohort study. Pol Arch Intern Med. 2026 Apr 29;136(4):17253. doi: 10.20452/pamw.17253. Epub 2026 Mar 17.
• Byambaa E, Roshanravan B, Berglund L. Lipoprotein(a) and CKD: Insights into New Therapeutic Opportunities. Clin J Am Soc Nephrol. 2025 Dec 2. doi: 10.2215/CJN.0000000968. Online ahead of print.
• Nicholls SJ, Nelson AJ, Michael LF. Oral agents for lowering lipoprotein(a). Curr Opin Lipidol. 2024 Dec 1;35(6):275-280. doi: 10.1097/MOL.0000000000000953. Epub 2024 Sep 25.
• Burvill A, Watts GF, Norman R, Ademi Z. Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease. J Clin Lipidol. 2024 Nov-Dec;18(6):e946-e956. doi: 10.1016/j.jacl.2024.08.012. Epub 2024 Aug 31.
• Dimitriadis K, Theofilis P, Iliakis P, Pyrpyris N, Dri E, Sakalidis A, Soulaidopoulos S, Tsioufis P, Fragkoulis C, Chrysohoou C, Tsiachris D, Tsioufis K. Management of dyslipidemia in coronary artery disease: the present and the future. Coron Artery Dis. 2024 Sep 1;35(6):516-524. doi: 10.1097/MCA.0000000000001375. Epub 2024 Apr 29.
• Karp A, Jacobs M, Barris B, Labkowsky A, Frishman WH. Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities. Cardiol Rev. 2025 Jul-Aug 01;33(4):352-358. doi: 10.1097/CRD.0000000000000667. Epub 2024 Feb 28.

Drugs

Indications